<DOC>
	<DOC>NCT00948558</DOC>
	<brief_summary>1. To compare the differences of citrate pharmacokinetics in healthy individuals and critically ill patients as well as the influential factors. 2. To validate a pharmacokinetic model which has been established in a formal paper. 3. To create a safe and effective RCA-CRRT protocol.</brief_summary>
	<brief_title>Citrate Pharmacokinetics and Regional Citrate Anticoagulation in CRRT</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>healthy individuals, nonepregnant diagnosed with acute renal failure according to RIFLE criteria ARF with hepatic insufficiency ARF with MODS or sepsis within informed consent used drugs with citrate within one week infused with blood,plasma or platelet or undergone plasma exchange therapy within 48 hours serious alkalosis with PH&gt;7.55 serious lactic acidosis not in resuscitation state</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>citrate anticoagulation</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>critically ill</keyword>
	<keyword>acute kidney failure</keyword>
</DOC>